<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2025-09-25 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft document entitled "Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry." The draft guidance document provides sponsors engaged in the development of regenerative medicine therapies for serious or life-threatening diseases or conditions with FDA's recommendations on the expedited development and review of these therapies. This draft guidance, when ...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2025-18653</p>
    <p><strong>Publication Date:</strong> 2025-09-25</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2025/09/25/2025-18653/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for">https://www.federalregister.gov/documents/2025/09/25/2025-18653/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2025-18653</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
